This Growth Stock is a Consensus Buy
It’s currently firing on all cylinders, and it earns an ‘A-rating’ in my Portfolio Grader.
Read MorePosted by Louis Navellier and the InvestorPlace Research Staff | Nov 1, 2021
It’s currently firing on all cylinders, and it earns an ‘A-rating’ in my Portfolio Grader.
Read MorePosted by Louis Navellier and the InvestorPlace Research Staff | Oct 29, 2021
It’s worth a closer look now as it’s bound to be crowned a winner again.
Read MorePosted by Louis Navellier and the InvestorPlace Research Staff | Oct 28, 2021
These names offer a smart way to play rising energy prices.
Read MorePosted by Louis Navellier and the InvestorPlace Research Staff | Oct 27, 2021
A rare bargain at an irrationally low valuation, now could be a prime opportunity.
Read MorePosted by Louis Navellier and the InvestorPlace Research Staff | Oct 23, 2021
It’s been in growth mode for over a decade, and its Covid-19 vaccine is going to continue to sell for the foreseeable future. Plus, the company has a solid product lineup outside of the spotlight vaccine.
Read More